Participant flow42

How many started, completed or left each group, period by period.

21 to 40 of 42

Period	Milestone	Group	Participants
Overall Study	Survival Population	Pemetrexed +/- Cisplatin or Carboplatin	0
Overall Study	Adverse Event Population	Lorlatinib	3
Overall Study	Adverse Event Population	LDK378 (Ceritinib)	1
Overall Study	Adverse Event Population	Alectinib	0
Overall Study	Adverse Event Population	Brigatinib	2
Overall Study	Adverse Event Population	Ensartinib	3
Overall Study	Adverse Event Population	Crizotinib	0
Overall Study	Adverse Event Population	Pemetrexed +/- Cisplatin or Carboplatin	0
Overall Study	COMPLETED	Lorlatinib	3
Overall Study	COMPLETED	LDK378 (Ceritinib)	1
Overall Study	COMPLETED	Alectinib	0
Overall Study	COMPLETED	Brigatinib	2
Overall Study	COMPLETED	Ensartinib	3
Overall Study	COMPLETED	Crizotinib	0
Overall Study	COMPLETED	Pemetrexed +/- Cisplatin or Carboplatin	0
Overall Study	NOT COMPLETED	Lorlatinib	0
Overall Study	NOT COMPLETED	LDK378 (Ceritinib)	0
Overall Study	NOT COMPLETED	Alectinib	0
Overall Study	NOT COMPLETED	Brigatinib	0
Overall Study	NOT COMPLETED	Ensartinib	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03737994/flow?page=2